Dr Hachemi Kadri

Contact

Hachemi Kadri
About
Teaching and learning
Research

About

I joined Kingston University, London in January 2022 where I currently hold the position of Senior Lecturer in Pharmaceutical Chemistry. Prior to this, I was awarded the prestigious MRC GCRF Fellowship and was appointed as an Assistant Professor  (Research) at the Chemistry Department, Durham University (January 2019-December 2021) where I also was a partner in the Global Network for the Neglected Tropical Diseases initiative. My MRC GCRF Fellowship research focused on developing innovative chemical approaches and tools to validate novel targets in Chagas disease and Leishmaniasis.

I completed my MPharm (Hons) degree at the University of Nottingham followed by a PhD in Medicinal Chemistry and Drug Design at the University of Cardiff, where I worked on the design, synthesis, and biological evaluation of novel anti-cancer agents. After my PhD, I worked on several drug discovery projects in key therapeutic areas including immuno-oncology, neurodegenerative and cardiovascular diseases at the University of Birmingham and later at Cardiff University

Academic responsibilities

Senior Lecturer in Pharmaceutical Chemistry

Qualifications

  • Ph.D. in Medicinal Chemistry and Drug Design, Cardiff University
  • MPharm (Hons) degree at the University of Nottingham
  • GPhC registered pharmacist

Teaching and learning

Undergraduate courses taught

Postgraduate courses taught

Research

Research in The Kadri Lab focuses on developing innovative chemical approaches for the discovery of novel therapeutics to address unmet global health needs particularly neglected tropical diseases (NTDs). Research is multidisciplinary spanning the fields of chemical biology, medicinal chemistry, computer-aided drug design, high throughput screening, protein crystallography, and biochemistry. 

Funding:

  • 2022-2023: RSC Research Fund grant
  • 2019-2021: GCRF Fellowship award.

Areas of specialism

  • Infectious diseases target validation and drug discovery
  • Modulation of protein-protein interactions for therapeutic purposes
  • Computer-aided drug design of novel therapeutic compounds

Research student supervision

Main supervision

Other supervision

Publications

Jump to: Article
Number of items: 17.

Article

Kadri, Hachemi, Taher, Taher E., Xu, Qin, Sharif, Maria, Ashby, Elizabeth, Bryan, Richard T., Willcox, Benjamin E. and Mehellou, Youcef (2020) Aryloxy diester phosphonamidate prodrugs of phosphoantigens (ProPAgens) as potent activators of Vγ9/Vδ2 T-cell immune responses. Journal of Medicinal Chemistry, 63(19), pp. 11258-11270. ISSN (print) 0022-2623

Miccoli, Ageo, Dhiani, Binar A., Thornton, Peter J., Lambourne, Olivia A., James, Edward, Kadri, Hachemi and Mehellou, Youcef (2020) Aryloxy triester phosphoramidates as phosphoserine prodrugs : a proof of concept study. ChemMedChem, 15(8), pp. 671-674. ISSN (print) 1860-7179

AlAmri, Mubarak A., Kadri, Hachemi, Alderwick, Luke J., Jeeves, Mark and Mehellou, Youcef (2018) The photosensitising clinical agent verteporfin is an inhibitor of SPAK and OSR1 kinases. ChemBioChem, 19(19), pp. 2072-2080. ISSN (print) 1439-4227

Mehellou, Youcef, Alamri, Mubarak A., Dhiani, Binar A. and Kadri, Hachemi (2018) C-terminal phosphorylation of SPAK and OSR1 kinases promotes their binding and activation by the scaffolding protein MO25. Biochemical and Biophysical Research Communications, 503(3), pp. 1868-1873. ISSN (print) 0006-291X

Kadri, Hachemi, Lambourne, Olivia A. and Mehellou, Youcef (2018) Niclosamide : a drug with many (re)purposes. ChemMedChem, 13(11), pp. 1088-1091. ISSN (print) 1860-7179

Barini, Erica, Miccoli, Ageo, Tinarelli, Federico, Mulholland, Katie, Kadri, Hachemi, Khanim, Farhat, Stojanovski, Laste, Read, Kevin D., Burness, Kerry, Blow, Julian J., Mehellou, Youcef and Muqit, Miratul M. K. (2018) The anthelmintic drug niclosamide and its analogues activate the Parkinson's disease associated protein kinase PINK1. ChemBioChem, 19(5), pp. 425-429. ISSN (print) 1439-4227

Salim, Mahboob, Knowles, Timothy J, Baker, Alfie T., Davey, Martin S., Jeeves, Mark, Sridhar, Pooja, Wilkie, John, Willcox, Carrie R., Kadri, Hachemi, Taher, Taher E., Vantourout, Pierre, Hayday, Adrian, Mehellou, Youcef, Mohammed, Fiyaz and Willcox, Benjamin E. (2017) BTN3A1 discriminates γδ T cell phosphoantigens from nonantigenic small molecules via a conformational sensor in its B30.2 domain. ACS Chemical Biology, 12(10), pp. 2631-2643. ISSN (print) 1554-8929

AlAmri, Mubarak A., Kadri, Hachemi, Dhiani, Binar A., Mahmood, Shumail, Elzwawi, Abdulrahman and Mehellou, Youcef (2017) WNK signaling inhibitors as potential antihypertensive drugs. ChemMedChem, 12(20), pp. 1677-1686. ISSN (print) 1860-7179

AlAmri, Mubarak A., Kadri, Hachemi, Alderwick, Luke J., Simpkins, Nigel S. and Mehellou, Youcef (2017) Rafoxanide and closantel inhibit SPAK and OSR1 kinases by binding to a highly conserved allosteric site on their C-terminal domains. ChemMedChem, 12(9), pp. 639-645. ISSN (print) 1860-7179

Osgerby, Laura, Lai, Yu-Chiang, Thornton, Peter J., Amalfitano, Joseph, Le Duff, Cécile S., Jabeen, Iqra, Kadri, Hachemi, Miccoli, Ageo, Tucker, James H. R., Muqit, Miratul M. K. and Mehellou, Youcef (2017) Kinetin riboside and its ProTides activate the Parkinson's disease associated PTEN-induced putative kinase 1 (PINK1) independent of mitochondrial depolarization. Journal of Medicinal Chemistry, 60(8), pp. 3518-3524. ISSN (print) 0022-2623

Kadri, Hachemi, Alamri, Mubarak A., Navratilova, Iva H., Alderwick, Luke J., Simpkins, Nigel S. and Mehellou, Youcef (2017) Towards the development of small-molecule MO25 binders as potential indirect SPAK/OSR1 kinase inhibitors. ChemBioChem, 18(5), pp. 460-465. ISSN (print) 1439-4227

Thornton, Peter J., Kadri, Hachemi, Miccoli, Ageo and Mehellou, Youcef (2016) Nucleoside phosphate and phosphonate prodrug clinical candidates. Journal of Medicinal Chemistry, 59(23), pp. 10400-10410. ISSN (print) 0022-2623

Karaaslan, Cigdem, Kadri, Hachemi, Coban, Tulay, Suzen, Sibel and Westwell, Andrew D. (2013) Synthesis and antioxidant properties of substituted 2-phenyl-1H-indoles. Bioorganic & Medicinal Chemistry Letters, 23(9), pp. 2671-2674. ISSN (print) 0960-894X

Kadri, H., Dale, T.C., Ewan, K.B.R. and Westwell, A.D. (2008) The design, synthesis and antitumour evaluation of novel small molecule inhibitors of the Dishevelled PDZ domain. European Journal of Cancer Supplements, 6(12), p. 137. ISSN (print) 1359-6349

Aiello, Stefania, Wells, Geoffrey, Stone, Erica L., Kadri, Hachemi, Bazzi, Rana, Bell, David R., Stevens, Malcolm F. G., Matthews, Charles S., Bradshaw, Tracey D. and Westwell, Andrew D. (2008) Synthesis and biological properties of benzothiazole, benzoxazole, and chromen-4-one analogues of the potent antitumor agent 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (PMX 610, NSC 721648). Journal of Medicinal Chemistry, 51(16), pp. 5135-5139. ISSN (print) 0022-2623

Ziedan, Noha I., Kadri, Hachemi and Westwell, Andrew D. (2008) The development of pro-apoptotic cancer therapeutics. Mini-Reviews in Medicinal Chemistry, 8(7), pp. 711-718. ISSN (print) 1389-5575

Kadri, Hachemi, Matthews, Charles S., Bradshaw, Tracey D., Stevens, Malcolm F. G. and Westwell, Andrew D. (2008) Synthesis and antitumour evaluation of novel 2- phenylbenzimidazoles. Journal of Enzyme Inhibition and Medicinal Chemistry, 23(5), pp. 641-647. ISSN (print) 1475-6366

This list was generated on Wed Nov 20 07:30:59 2024 GMT.